Cooke & Bieler LP Raises Stake in Perrigo Company plc $PRGO

Cooke & Bieler LP raised its position in Perrigo Company plc (NYSE:PRGO) by 11.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,680,411 shares of the company’s stock after purchasing an additional 381,290 shares during the period. Cooke & Bieler LP owned 2.68% of Perrigo worth $81,963,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Amundi grew its stake in shares of Perrigo by 11.7% during the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after purchasing an additional 556 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Perrigo by 126.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock worth $32,520,000 after acquiring an additional 647,982 shares in the last quarter. United Services Automobile Association purchased a new position in shares of Perrigo in the 1st quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Perrigo by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after acquiring an additional 32,151 shares during the last quarter. Finally, Geneos Wealth Management Inc. raised its position in shares of Perrigo by 439.1% during the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares in the last quarter. 95.91% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Zacks Research downgraded Perrigo from a “hold” rating to a “strong sell” rating in a report on Friday, November 7th. Canaccord Genuity Group reduced their price objective on shares of Perrigo from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Wall Street Zen downgraded shares of Perrigo from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. JPMorgan Chase & Co. cut their price target on shares of Perrigo from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Perrigo in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $20.33.

Insider Activity

In other Perrigo news, Director Geoffrey M. Parker purchased 7,500 shares of Perrigo stock in a transaction dated Wednesday, November 12th. The stock was acquired at an average cost of $14.18 per share, with a total value of $106,350.00. Following the acquisition, the director directly owned 17,375 shares of the company’s stock, valued at $246,377.50. This represents a 75.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.40% of the company’s stock.

Perrigo Price Performance

Perrigo stock opened at $14.70 on Monday. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.51 and a quick ratio of 1.44. The business has a 50 day simple moving average of $13.85 and a 200-day simple moving average of $19.51. Perrigo Company plc has a 12 month low of $12.17 and a 12 month high of $30.93. The stock has a market capitalization of $2.02 billion, a PE ratio of -38.69, a price-to-earnings-growth ratio of 1.32 and a beta of 0.40.

Perrigo (NYSE:PRGO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.05. The company had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Perrigo had a negative net margin of 1.21% and a positive return on equity of 9.16%. Perrigo’s revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.81 EPS. Perrigo has set its FY 2025 guidance at 2.700-2.80 EPS. Equities analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 16th. Shareholders of record on Friday, November 28th were given a dividend of $0.29 per share. The ex-dividend date was Friday, November 28th. This represents a $1.16 annualized dividend and a yield of 7.9%. Perrigo’s payout ratio is presently -305.26%.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.